Ayer Capital revealed a 5.21% passive stake in Genesis Biopharma, Inc. (GNBP). According to the 13G filing on October 21th, Ayer Capital now has 4.8 million shares in GNBP. This is a brand new position because Ayer Capital did not have any share in the stock before. GNBP has lost 17% year to date, and is now trading at $1.13. No other hedge fund in our tracking list has filed position in GNBP yet.
Ayer Capital is a small private company categorized under General Brokerage. The firm has an investment team of 9. Its managed funds are not open to outsiders.
Genesis Biopharma, Inc. is a biopharmaceutical company, which engages in the development and sales of drugs and other clinical solutions for underserved diseases, including metastatic cancers and lethal infectious diseases. The company was formerly known as Freight Management Corp before March 15, 2010. The company was founded in 2007 and is headquartered in Los Angeles, California.